SCHEMBL263873

SCHEMBL263873

Cc1nc(-c2ccc(N)cc2)sc1CCO

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.46
ZAP70 P43403 1/20 0.46
SYK P43405 1/20 0.46
MAPT P10636 14/20 0.45
TP53 P04637 8/20 0.45
LMNA P02545 6/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
APP P05067 1/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
THRB P10828 3/20 0.43
CYP1A2 P05177 1/20 0.41
HRH2 P25021 1/20 0.41
HRH1 P35367 1/20 0.41
HRH4 Q9H3N8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3372003 0.84 MAPT (0.55) MAPTTP53LMNAKDM4ENPC1
SCHEMBL260421 0.84 LMNA (0.54) MAPTTP53LMNAKDM4ENPC1
SCHEMBL3374725 0.81 MAPT (0.60) SRCZAP70SYKMAPTNPC1
SCHEMBL279195 0.80 MAPT (0.41) MAPTTP53LMNAKDM4ENPC1
SCHEMBL6319677 0.80 SRC (0.46) SRCZAP70SYKMAPTTP53
SCHEMBL261442 0.79 SRC (0.47) SRCZAP70SYKMAPTTP53
SCHEMBL260345 0.79 RAB9A (0.60) MAPTTP53LMNAAPPGAA
SCHEMBL260156 0.76 MAPT (0.39) MAPTTP53LMNAKDM4ENPC1
SCHEMBL260103 0.75 MAPT (0.56) SRCZAP70SYKMAPTLMNA
SCHEMBL12641895 0.74 APP (0.51) MAPTTP53KDM4ENPC1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134010-B2 4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenylamine; N-{4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenyl}-acetamide; or4-Methyl-5-(2-nitrooxy-ethyl)-2-(4-nitro-phenyl)-thiazole; cardiovascular, gastrointestinal, inflammatory, respiratory disease RENOPHARM LTD. (IL) 2012-03-13 US disclosed
US-8134010-B2 4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenylamine; N-{4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenyl}-acetamide; or4-Methyl-5-(2-nitrooxy-ethyl)-2-(4-nitro-phenyl)-thiazole; cardiovascular, gastrointestinal, inflammatory, respiratory disease RENOPHARM LTD. (IL) 2012-03-13 US disclosed
US-20080233163-A1 Thiazole-based Nitric Oxide donors having Acyl substuent(s) and uses thereof RENOPHARM LTD. (IL) 2008-09-25 US disclosed
US-20080233163-A1 Thiazole-based Nitric Oxide donors having Acyl substuent(s) and uses thereof RENOPHARM LTD. (IL) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080233163-A1 Thiazole-based Nitric Oxide donors having Acyl substuent(s) and uses thereof NOS2, NOS1, SQOR SRC 1843/4885ZAP70 1363/4885SYK 475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.